In retrospective studies that enrolled only NSCLC patients, the onset of CIP occurred earlier when PD-1/PD-L1 inhibitors were combined with other treatments (Table 2). This evidence concerns the gene PDCD1 and hereditary sensory and autonomic neuropathy.